Brazil's health regulator Anvisa has cleared the first human trial of Vivaxin, a vaccine aimed at malaria caused by the Plasmodium vivax parasite. Published Wednesday, October 7, 2026, the approval marks a rare case of a domestically developed vaccine advancing through regulatory review in Latin America's largest economy.
CTVacinas at the Federal University of Minas Gerais (UFMG), the University of São Paulo (USP), and laboratory Cristália developed the vaccine through a partnership. Anvisa approved the clinical development dossier and research process in Resolution-RE No. 3,956 on October 6, 2026.
The Clinical Framework
The Phase 1 trial will assess safety, reactions to the injection, and immune response in 48 healthy volunteers aged 18 to 59 who have never had malaria. Participants will receive three doses, 28 days apart, and researchers will follow them for 360 days at the clinical research centre of the Hospital das Clínicas of UFMG in Belo Horizonte. The study is double-blind, randomised, and placebo-controlled.
Phase 1 won't establish whether the vaccine protects people. Researchers intend the results to guide later trial phases, and public approval remains years away. Vivaxin combines three variants of a parasite surface protein called PvCSP in one molecule, aiming to block the parasite before it reaches the liver.
Animal studies showed promise. Brazilian research reports say the formulation fully prevented infection in some mice. But the developers caution that mouse results don't predict how people will respond, and vaccines that work in animals frequently fail in humans.
The Market Gap
The World Health Organization-recommended vaccines RTS,S and R21/Matrix-M target Plasmodium falciparum, the dominant species in sub-Saharan Africa. That leaves a significant gap. Plasmodium vivax caused about 63% of estimated malaria cases in the Americas in 2024, according to the WHO's World Malaria Report. The developers say no vaccine against vivax malaria is available to the public anywhere in the world.
Brazil recorded 118,037 malaria cases in 2025, with more than 99% concentrated in the Amazon region. Ricardo Gazzinelli, who coordinates CTVacinas, said the disease keeps people from working and carries substantial socioeconomic consequences.
Public Investment and Private Partnership
The project receives funding from several government sources: Brazil's science ministry, its national science fund, the Finep innovation agency, and the Ministry of Health. Federal support and institutional collaboration reflect Brazil's effort to build domestic vaccine capacity while tackling a disease that disproportionately affects its most remote regions.
The trial site in Belo Horizonte, capital of Minas Gerais, keeps research and development within existing institutional infrastructure, without requiring new facilities or relocated expertise. Those efficiency gains matter when government resources remain constrained.
Later trial phases must show actual protection before any regulatory pathway toward public approval opens. Vaccine development is complex, and the standard regulatory timeline means widespread availability remains distant. For now, the WHO continues advising travelers and residents in endemic areas to follow established medical prevention protocols.
Why This Matters:
Vivaxin's regulatory clearance signals that Brazil's institutional capacity for drug development can function without heavy-handed government intervention beyond basic safety oversight. The vaccine addresses a genuine market failure: no existing solution for vivax malaria despite its prevalence in the Americas. That suggests private enterprise and university research can identify and pursue opportunities even in developing markets. The multi-institutional partnership shows how federally-funded research centers and private laboratories can coordinate effectively. Success would reduce Brazil's malaria burden and potentially lower healthcare costs tied to the disease's socioeconomic impact. Failure or delays would reinforce that even promising domestic innovation faces years of regulatory scrutiny before reaching patients. Either outcome will inform how policymakers assess Brazil's capacity to develop future therapies independently, rather than import solutions or accept dependence on foreign vaccine makers.